OncLive: HERTHENA-Breast04 Is Set to Delineate the Role of HER3-Targeted Therapy in Advanced HR+ Breast Cancer
June 4, 2026
OncLive: HERTHENA-Breast04 Is Set to Delineate the Role of HER3-Targeted Therapy in Advanced HR+ Breast Cancer
June 4, 2026
OncLive: HERTHENA-Breast04 Is Set to Delineate the Role of HER3-Targeted Therapy in Advanced HR+ Breast Cancer
June 4, 2026
MedPage Today: Accumulating Evidence Lifts GLP-1s to Clinical Trial for Breast Cancer Prevention
June 4, 2026
Healio: HemOnc Today announces 2026 Disruptive Innovators
June 4, 2026
San Antonio Report: UT San Antonio lands millions in new state funding
June 3, 2026
The Washington Post: The science around GLP-1 drugs and cancer is suddenly getting a lot more interesting
June 3, 2026
Colton Jones, MD, hematology and oncology fellow at UT Health San Antonio, the academic health center of The University of Texas at San Antonio (UT San Antonio), was quoted in this article. Read More (subscription required)